ZEQUANDA Trademark

Trademark Overview

On Wednesday, May 27, 2015, a trademark application was filed for ZEQUANDA with the United States Patent and Trademark Office. The USPTO has given the ZEQUANDA trademark a serial number of 86642019. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, March 15, 2024. This trademark is owned by Glaxo Group Limited. The ZEQUANDA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines
zequanda

General Information

Serial Number86642019
Word MarkZEQUANDA
Filing DateWednesday, May 27, 2015
Status710 - CANCELLED - SECTION 8
Status DateFriday, March 15, 2024
Registration Number5279082
Registration DateTuesday, September 5, 2017
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 12, 2016

Trademark Statements

Goods and ServicesPharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, March 15, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGlaxo Group Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS
GB
Party NameGlaxo Group Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS
Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS

Trademark Events

Event DateEvent Description
Friday, March 15, 2024CANCELLED SEC. 8 (6-YR)
Wednesday, November 9, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, November 9, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, November 9, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, November 9, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, November 9, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, September 5, 2022COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Monday, December 9, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, December 9, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, September 5, 2017REGISTERED-PRINCIPAL REGISTER
Tuesday, August 1, 20171(B) BASIS DELETED; PROCEED TO REGISTRATION
Friday, June 2, 2017NOTICE OF ALLOWANCE CANCELLED
Saturday, June 24, 2017CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, June 2, 2017TEAS POST PUBLICATION AMENDMENT RECEIVED
Saturday, December 3, 2016NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 1, 2016SOU EXTENSION 1 GRANTED
Thursday, December 1, 2016SOU EXTENSION 1 FILED
Thursday, December 1, 2016SOU TEAS EXTENSION RECEIVED
Tuesday, June 7, 2016NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 12, 2016OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 12, 2016PUBLISHED FOR OPPOSITION
Wednesday, March 23, 2016NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, March 9, 2016LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, March 2, 2016APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, March 1, 2016TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, March 1, 2016CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, February 22, 2016ASSIGNED TO LIE
Tuesday, February 16, 2016TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Thursday, October 29, 2015NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, October 29, 2015LETTER OF SUSPENSION E-MAILED
Thursday, October 29, 2015SUSPENSION LETTER WRITTEN
Wednesday, October 21, 2015PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Wednesday, October 21, 2015TEAS VOLUNTARY AMENDMENT RECEIVED
Tuesday, September 15, 2015NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, September 15, 2015NON-FINAL ACTION E-MAILED
Tuesday, September 15, 2015NON-FINAL ACTION WRITTEN
Tuesday, September 8, 2015ASSIGNED TO EXAMINER
Tuesday, June 23, 2015TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, June 2, 2015NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, May 30, 2015NEW APPLICATION ENTERED

Related Keywords

zequanda pharmaceutical treatment disorders substances preparations diseases ophthalmic genitourinary hepatological oncological